|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 2018加拿大心境障碍与焦虑障碍治疗协作组/国际双相障碍学会指南:双相障碍的管理显示文摘加拿大心境障碍与焦虑障碍治疗协作组(Canadian Network for Mood and Anxiety Treatments,CANMAT)曾于2005年发布了第1版双相障碍管理指南,并分别于2007、2009和2013年对该指南进行了更新,其中最近的2次更新是与国际双相障碍学会(International Society for Bipolar Disorders,ISBD)合作完成。2018版CANMAT/ISBD双相障碍治疗指南(以下简称指南)反映了自2005年首版指南发表以来本领域取得的重大进展,包括疾病诊断与疾病管理的更新以及药物治疗与心理治疗的近期研究进展。这些前沿进展中综合考虑了循证证据的级别,并基于治疗疗效、临床实践经验、安全性、耐受性和药物导致的转相风险等,对一线、二线及三线治疗方案进行了简明而清晰的推荐。本指南中新增内容涵盖了双相Ⅰ型障碍(BD-Ⅰ)的躁狂发作急性期、抑郁发作急性期和双相障碍维持期的一线及二线治疗推荐等级划分。这种对治疗推荐等级的划分综合考虑了治疗方法对双相障碍不同时相的影响,将进一步帮助临床医生做出基于循证证据的治疗决策。锂盐、喹硫平、双丙戊酸盐、阿塞那平、阿立哌唑、帕利哌酮、利培酮和卡利拉嗪单药或联合使用被推荐为躁狂发作急性期的一线治疗选择。BD-Ⅰ抑郁期的一线治疗选择包括喹硫平、鲁拉西酮、锂盐、拉莫三嗪单药,鲁拉西酮联合锂盐或双丙戊酸盐或拉莫三嗪辅助治疗。尽管急性期治疗有效的药物通常应继续用于BD-Ⅰ的维持期治疗,但也存在一些特殊情况(例如抗抑郁药)。现有数据表明,锂盐、喹硫平、双丙戊酸盐、拉莫三嗪、阿塞那平和阿立哌唑单药或联合治疗应被视为维持治疗的初始或更换治疗方案时的一线选择。除了探讨BD-Ⅰ的相关问题外,本指南中还对双相Ⅱ型障碍(BD-Ⅱ)的临床管理进行了系统回顾并给予治疗推荐,同时针对特殊人群也有相关推荐,如处于各个生殖周期的女性、儿童、青少年和老年人。此外,本指南中还讨论了特定精神疾病及共病(如物质滥用、焦虑障碍和代谢性疾病)的影响。最后,本指南中概述了安全性和药物监测的相关问题。CANMAT/ISBD工作组希望本指南能够成为全球临床医生的实用工具。 | Lakshmi N Yatham Sidney H Kennedy Sagar V Parikh Ayal Sehaffer David J Bond Benicio N Frey Verinder Sharma Benjamin I Goldstein Soham Rej Serge Beaulieu Martin Alda Glenda MaeQueen Roumen V Milev Arun Ravindran Claire O'Donovan Diane Mclntosh Raymond W Lam Gustavo Vazquez Flavio Kapczinski Roger S Melntyre Jan Kozicky Shigenobu Kanba Beny Lafer Trisha Suppes Joseph R Calabrese Eduard Vieta Gin Malhi Robert M Post Michael Berk 胡晨(译) 王刚(译) | 2019 | 中华精神科杂志2019，52，1： | 25 |
| 2 | Catalytic Regioselective Sulfonylation ofα-Chelatable Alcohols:Scope and Mechanistic Insight显示文摘 | Michael J M Rajappa V Joseph M P | 2002 | J Am Chem Soc2002，124，14： | 1 |
| 3 | Epidemic History and Evolutionary Dynamics of Hepatitis B Virus Infection in Two Remote Communities in Rural Nigeria显示文摘 | Joseph CF Gilberto V Michael AP | 2010 | PLoS One2010，5，7： | 1 |
| 4 | Incerased risk in esophageal obstruction with slow- release medications显示文摘 | Simko V Joseph D Michael S | 1997 | J Assoc Acad Minor Phys1997，8，2： | 1 |
| 5 | Increased risk in esophageal ob-struction with slow-release medications显示文摘 | Simko V Joseph D Michael S | 1997 | {H}Journal of the Association for Academic Minority Physicians1997，，02： | 1 |
| 6 | Biomarkers of acute kidney injury 显示文摘 | Vishal S Vaidya Michael A Ferguson Joseph V Bonven- tre | 2008 | Annu Rev Pharmacol Toxicol2008，48，17： | 1 |
| 7 | Litigation risk ,audit quality, and audit fees: evidence from initial public offerings 显示文摘 | Pamgopal V Joseph P W Michael W | 2008 | The Accounting Review2008，83，： | 1 |
| 8 | Factors associated with success of telaprevir-and boceprevir-based triple therapy for hepatitis C virus infection显示文摘AIM To evaluate new therapies for hepatitis C virus(HCV), data about real-world outcomes are needed.METHODS Outcomes of 223 patients with genotype 1 HCV who started telaprevir-or boceprevir-based triple therapy(May 2011-March 2012) at the Mount Sinai Medical Center were analyzed. Human immunodeficiency viruspositive patients and patients who received a liver transplant were excluded. Factors associated with sustained virological response(SVR24) and relapse were analyzed by univariable and multivariable logistic regression as well as classification and regression trees. Fast virological response(FVR) was defined as undetectable HCV RNA at week-4(telaprevir) or week-8(boceprevir). RESULTS The median age was 57 years, 18% were black, 44% had advanced fibrosis/cirrhosis(FIB-4 ≥ 3.25). Only 42%(94/223) of patients achieved SVR24 on an intention-totreat basis. In a model that included platelets, SVR24 was associated with white race [odds ratio(OR) = 5.92, 95% confidence interval(CI): 2.34-14.96], HCV sub-genotype 1b(OR = 2.81, 95%CI: 1.45-5.44), platelet count(OR = 1.10, per x 104 cells/μL, 95%CI: 1.05-1.16), and IL28 B CC genotype(OR = 3.54, 95%CI: 1.19-10.53). Platelet counts > 135 x 103/μL were the strongest predictor of SVR by classification and regression tree. Relapse occurred in 25%(27/104) of patients with an end-oftreatment response and was associated with non-FVR(OR = 4.77, 95%CI: 1.68-13.56), HCV sub-genotype 1a(OR = 5.20; 95%CI: 1.40-18.97), and FIB-4 ≥ 3.25(OR = 2.77; 95%CI: 1.07-7.22). CONCLUSION The SVR rate was 42% with telaprevir-or boceprevirbased triple therapy in real-world practice. Low platelets and advanced fibrosis were associated with treatment failure and relapse. | Kian Bichoupan Neeta Tandon Valerie Martel-Laferriere Neal M Patel David Sachs Michel Ng Emily A Schonfeld Alexis Pappas James Crismale Alicia Stivala Viktoriya Khaitova Donald Gardenier Michael Linderman William Olson Ponni V Perumalswami Thomas D Schiano Joseph A Odin Lawrence U Liu Douglas T Dieterich Andrea D Branch | 2017 | World Journal of Hepatology2017，9，11： | 0 |
| 9 | 超体质量减肥手术后体形塑造术并发症:评估和预防策略显示文摘【摘要】体质量大量减轻的患者对整形医师来说是一个特别的挑战。回顾这些问题,对不是专门研究该领域的外科医师是有价值的。手术要想取得良好结果,需要综合的围手术方法、开始时正确的患者选择和正确的手术预期。术中注意事项(如低体温症的预防和血栓栓塞的预防)对改善结果和降低发病率均有积极作用。适当的术后护理可让患者和医师对结果都满意。 | Joseph Michaels V Devin Coon J. Peter Rubin 朱丽娜(译) 魏峰(译) 高景恒(译) 张晨(译) | 2013 | 中国美容整形外科杂志2013，24，7： | 0 |
| 10 | 超体质量减肥手术后体形塑造术的并发症:术后处理和治疗显示文摘【摘要】体形塑造患者适当的术后管理对术后远期的满意结果是必不可少的。普遍问题,如引流管处理、营养和活动限制,与所有患者均相关。尽管术后并发症十分罕见,但本文描述的处理轻度并发症的有效措施也是非常有价值的。 | Joseph Michaels V Devin Coon J. Peter Rubin 朱丽娜(译) 魏峰(译) 高景恒(译) 张晨(译) | 2013 | 中国美容整形外科杂志2013，24，7： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员